Sanofi Applauds Supreme Court Ruling Supporting Scientific Innovation By Striking Down Amgen's Asserted PCSK9 Patent Claims In Amgen Vs Sanofi
Portfolio Pulse from Happy Mohamed
The US Supreme Court has ruled in favor of Sanofi (NASDAQ:SNY) in the Amgen v. Sanofi case, affirming that Amgen's asserted PCSK9 patent claims are invalid. This decision supports scientific innovation and prevents potential increases in drug prices.
May 18, 2023 | 3:57 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Sanofi wins the Amgen v. Sanofi case, as the US Supreme Court invalidates Amgen's PCSK9 patent claims, supporting scientific innovation.
The Supreme Court's ruling in favor of Sanofi invalidates Amgen's PCSK9 patent claims, which is a positive outcome for Sanofi. This decision supports scientific innovation and prevents potential increases in drug prices, which could benefit Sanofi's reputation and stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
NEGATIVE IMPACT
Amgen loses the Amgen v. Sanofi case, as the US Supreme Court invalidates its asserted PCSK9 patent claims, potentially impacting its market position.
The Supreme Court's ruling against Amgen invalidates its PCSK9 patent claims, which is a negative outcome for the company. This decision supports scientific innovation and prevents potential increases in drug prices, which could negatively impact Amgen's market position and stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100